The newly cleared Rembra platform is designed to help healthcare providers manage rising demand for imaging services while improving operational efficiency and access to high-quality diagnostics. According to Philips, the platform extends the application of computed tomography across radiology and radiation therapy, enabling more integrated workflows and coordinated patient management. The systems aim to address clinical complexity by supporting faster imaging processes and more streamlined decision-making pathways.

Within the platform, Rembra CT features an 85-cm bore and is engineered for high-throughput environments, allowing up to 270 exams per day across emergency, critical care and interventional settings. Meanwhile, Rembra RT and Areta RT bring similar imaging capabilities into radiation therapy, supporting treatment planning with high-fidelity imaging, an extended field of view and next-generation 4DCT functionality. Collectively, the Rembra platform establishes a unified CT ecosystem designed to operate across the full care continuum.

Dan Xu, business leader of CT at Philips, said:
“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions. With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”

The system has been engineered to optimize the entire imaging workflow, from acquisition to reconstruction. By leveraging AI, it reduces system noise, improves image clarity, and accelerates clinical processes. Designed for seamless integration, the platform delivers PACS-native outputs and embeds directly into existing workflows. Spectral imaging enables the analysis of how tissues absorb varying X-ray energy levels, allowing detector-based systems to generate multiple spectral outputs from a single scan without compromising scan time or performance.

The technology is intended for broad clinical application, including radiology, interventional radiology, and cardiology. It also supports oncology workflows, particularly in treatment preparation and radiation therapy planning. The system combines high-definition conventional imaging with advanced spectral capabilities, while AI-driven reconstruction delivers enhanced image quality with reduced noise. Additionally, the platform is designed to lower radiation dose without affecting diagnostic output and can cut energy consumption by up to 45%.

Powered by third-generation Nano-panel Precise dual-layer detector technology, the system significantly improves processing efficiency. It can reconstruct up to 145 images per second and complete full exams in under 30 seconds, enabling throughput of up to 270 exams daily. This represents a twofold speed increase compared to earlier models. The platform builds on proprietary Spectral Precise Imaging technology, incorporating deep learning to refine imaging outcomes.

Dan Xu, Business Leader of CT at Philips, said:
“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets. By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”

The partnership, initially established in 2024, was designed to support the integration of artificial intelligence across imaging workflows. At its core, the initiative combines DeepHealth’s AI-driven breast cancer screening tools with GE HealthCare’s Senographe Pristina mammography platform. Since then, both companies have progressively expanded the scope of their collaboration, including plans to extend their offerings beyond the U.S. market and enhance the capabilities of their integrated solutions.

Recent developments center on DeepHealth’s Breast Suite, a cloud-based platform comprising modular and interoperable applications tailored for breast imaging environments. When integrated with GE HealthCare’s Pristina Via system, the suite is positioned to enable scalable and efficient screening programs. The updated Breast Suite introduces additional tools designed for compatibility with GE HealthCare systems, including ProFound Pro, which combines Cancer Detection capabilities with Automated Density Assessment. These features provide automated lesion localization, consistent density classification, and improved diagnostic support. The Safeguard Review functionality further enhances workflows by identifying complex cases that may require secondary evaluation.

Commenting on the collaboration, Jyoti Gupta, president and CEO, Women’s Health and X-ray at GE HealthCare, said:
“At GE HealthCare, we’re advancing women’s health through precision care built around the unique needs of women and enhanced by the power of AI. By integrating Breast Suite AI with our Pristina Via mammography system, we’re helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women.”

Dr. Niccolo Stefani, business leader, Population Health & Clinical AI, DeepHealth, added:
“At DeepHealth, we are committed to bringing the next era of AI-powered health informatics to help stage shift disease. Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions.”

The expanded initiative reflects a continued push toward improving clinical accuracy, workflow efficiency, and global accessibility of AI mammography technologies, reinforcing both companies’ commitment to advancing women’s health through data-driven imaging solutions.

In preparation for the rollout, the European Medicines Agency has scheduled an online information session on 24 April 2026. The session will outline key elements of the Breakthrough Devices framework and address practical considerations for stakeholders intending to participate. This step is expected to help manufacturers better understand procedural requirements and align early with regulatory expectations.

The pilot draws from the recently adopted MDCG 2025-9 guidance issued by the Medical Device Coordination Group. It also aligns with broader regulatory revisions proposed by the European Commission in December 2025, which introduced new provisions under Article 52a of the Medical Devices Regulation and Article 48a of the In Vitro Diagnostic Regulation. These updates aim to formalise a future framework for breakthrough medical technologies within the EU.

Positioned as a strategic move, the programme reinforces efforts to foster an innovation-oriented regulatory landscape across Europe. To secure a breakthrough designation, manufacturers must seek an opinion from the agency’s expert panels, with additional guidance and application templates expected ahead of the launch. The pilot also supports wider objectives tied to public health priorities, ensuring that advanced medical technologies entering the EU market continue to meet stringent quality, safety, and performance benchmarks. The Breakthrough Devices pilot is therefore expected to play a defining role in shaping future regulatory processes while strengthening confidence in high-impact innovations. The Breakthrough Devices pilot further underlines the EU’s commitment to balancing innovation with robust oversight.

The integrated solution brings together real-time MRI capabilities with MR-conditional interventional tools and structured clinical workflows. It builds on a partnership formalised in September 2025, when the two companies aligned their expertise—pairing Siemens Healthineers’ imaging technologies with Cook Medical’s procedural specialisation. The system incorporates devices specifically developed for MRI environments alongside the Magnetom Free.XL platform, creating a unified framework for interventional imaging and treatment delivery.

Within the suite, multiple components are integrated to streamline clinical use and expand procedural capabilities:

• Advanced imaging technology designed for real-time guidance during interventions
• Purpose-built interventional devices tailored for MRI compatibility
• Suite planning support and clinical education resources
• Integration with SIR VIRTEX, a clinical data registry and analytics platform
• Continuous data feedback to enhance procedural learning and outcomes

The companies state that this MRI Suite launch enables physicians to perform procedures that benefit from enhanced soft-tissue visibility while avoiding radiation exposure. Applications include oncology and soft-tissue interventions, with use cases spanning biopsies, ablations, and procedures in pediatric and cardiac care. According to Peter Polverini III, VP of Cook Medical’s iMRI division, “The iMRI Suite is more than a technology; it’s a fundamental shift in how we approach intervention. By bringing together advanced imaging, purpose-built devices, and integrated workflows, we are enabling physicians to see more, treat with greater precision, and ultimately deliver better outcomes without exposing patients or care teams to radiation.”

Pete Yonkman, president of Cook Medical and Cook Group, added: “MRI offers unique advantages for image-guided intervention, particularly for procedures involving soft tissue. Through our collaboration with Siemens Healthineers and leading clinicians, we are working to advance the development of radiation-free interventional approaches.” Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers, said: “At Siemens Healthineers, it is our goal to elevate health globally. Magnetom Free.XL is designed to unlock the full potential of MR in the interventional suite, expanding the imaging toolbox by matching the right modality to the right patient at the right time.”

The Limitations of Traditional Maintenance Strategies

Reactive maintenance is perhaps the most disruptive and costly approach in a clinical setting. When a vital piece of equipment fails unexpectedly, it can lead to canceled procedures, emergency repair costs, and, most importantly, compromised patient care. Preventive maintenance, while an improvement, often leads to “over-maintenance” or “under-maintenance.” Servicing a machine simply because a calendar date has arrived can result in unnecessary downtime and the premature replacement of perfectly functional components. Conversely, a machine that is heavily used might develop a fault between scheduled services, leading to a breakdown that preventive schedules failed to catch. Predictive maintenance addresses these inefficiencies by basing maintenance actions on the actual condition and performance of the equipment.

The Technological Engine: IoT and Data Analytics

At the heart of any predictive maintenance strategy is the continuous flow of data from the equipment to a central monitoring system. Modern biomedical devices are increasingly “smart,” equipped with internal sensors that track everything from temperature and vibration to power consumption and duty cycles. By integrating these devices into a hospital-wide IoT network, clinical engineers can gain a holistic view of the entire asset fleet. Data analytics platforms then process this information, using historical performance data to establish a “normal” baseline for each device. When the system detects a subtle deviation from this baseline such as a slight increase in operating temperature or a minor change in a motor’s vibration pattern it can flag the device for inspection long before a human operator would notice a problem.

Enhancing Patient Safety and Clinical Uptime

The most compelling argument for adopting predictive maintenance in healthcare is its direct impact on patient safety. In high-stakes environments like intensive care units or operating rooms, equipment failure is not just an inconvenience it is a life-threatening risk. By anticipating failures, hospitals can ensure that backup units are ready or that repairs are conducted during low-usage periods, such as overnight or between scheduled surgeries. This level of foresight eliminates the chaos associated with emergency repairs and allows clinical teams to focus entirely on patient care with full confidence in their technology. Moreover, predictive maintenance ensures that devices are always operating at their peak calibrated performance, which is essential for accurate diagnostics and effective treatment.

Cost Optimization and Asset Lifecycle Extension

From a financial perspective, predictive maintenance offers significant advantages over traditional models. By intervening only when necessary, hospitals can reduce the labor and parts costs associated with unnecessary preventive servicing. Additionally, because the system catches minor issues before they escalate into major mechanical failures, the overall cost of repairs is typically lower. Over the long term, this proactive care extends the useful life of the asset. A well-monitored machine that never experiences a catastrophic failure will naturally last longer and provide a better return on investment than one that is subject to the stresses of repeated breakdowns and emergency fixes. This optimization of the maintenance cycle allows for more strategic capital planning and better budget allocation across the biomedical department.

Integration with Hospital Information Systems

To be truly effective, predictive maintenance data should not exist in a silo. Integrating these insights with broader Hospital Information Systems (HIS) and Computerized Maintenance Management Systems (CMMS) creates a powerful ecosystem for healthcare management. When a predictive alert is triggered, the system can automatically generate a work order, check the inventory for necessary spare parts, and even look at the clinical schedule to suggest the best time for the technician to access the device. This level of automation reduces the administrative burden on clinical engineers and ensures that maintenance activities are perfectly aligned with the hospital’s operational flow.

Challenges in Implementing Data-Driven Maintenance Models

Despite its clear benefits, the transition to predictive maintenance is not without obstacles. One of the primary challenges is data interoperability. Hospitals often have a diverse mix of equipment from different manufacturers, many of which use proprietary data formats. Creating a unified platform that can ingest and analyze data from multiple sources requires significant technical expertise and investment. Furthermore, there is the human element: clinical engineering teams must be trained to work with data analytics and AI-driven alerts. Moving from a “wrench-turning” culture to a “data-interpreting” culture requires a shift in mindset and ongoing professional development.

HHM Global observes that security is another critical concern. As biomedical devices become more connected, they also become potential entry points for cyberattacks. A predictive maintenance system must be built on a secure foundation, with robust encryption and strict access controls to protect both the equipment’s operational integrity and any patient data that might be associated with the device’s usage logs. Ensuring that the pursuit of maintenance efficiency does not compromise the hospital’s cybersecurity posture is a paramount responsibility for IT and biomedical leadership.

The Role of Artificial Intelligence and Future Trends

As artificial intelligence (AI) and machine learning (ML) continue to evolve, the capabilities of predictive maintenance will only grow. Future systems will likely move beyond simple threshold-based alerts to complex “prescriptive” analytics. Not only will the system predict a failure, but it will also recommend the specific repair steps and provide a probability score for different outcomes. We may also see the rise of “digital twins,” where a virtual model of a physical piece of equipment is maintained in the cloud. This digital twin can be used to simulate different usage scenarios and stress-test the equipment without taking the physical unit out of service. This level of sophistication will make biomedical equipment management more precise and predictable than ever before.

In conclusion, the adoption of predictive maintenance represents a fundamental shift in how we manage the lifeblood of modern medicine. By moving away from the limitations of the past and embracing the data-driven possibilities of the future, healthcare organizations can create a more resilient, efficient, and safer environment for both staff and patients. The journey toward a fully predictive clinical environment requires investment in technology and people, but the results higher uptime, lower costs, and better care make it an essential path for any forward-looking healthcare system. The era of waiting for things to break is over the era of knowing they might break and stopping it before it happens has begun.

The Economic Imperative for Financial Flexibility

Traditional procurement methods often force healthcare administrators into difficult choices between maintaining a healthy balance sheet and providing clinicians with the latest diagnostic tools. When a facility chooses a CAPEX approach, it locks up liquidity in a depreciating asset. This frozen capital cannot be easily redeployed for urgent operational needs or emergency upgrades. In contrast, equipment as a service allows for a pay-per-use or monthly subscription model. This ensures that cash flow remains predictable and manageable, reflecting the actual revenue generated by the equipment. This synchronization of cost and revenue is particularly vital for private clinics and community hospitals that operate on thin margins and require high levels of fiscal transparency.

The transition to an OPEX-centric model also simplifies the accounting complexities associated with asset depreciation and tax implications. Under many equipment as a service agreements, the service provider retains ownership and responsibility for the asset’s lifecycle. This means the healthcare provider does not have to worry about the declining value of the machine or the eventual costs of decommissioning and disposal. Instead, they focus on the clinical value delivered. This shift essentially transforms a lumpy, unpredictable capital expense into a smooth, recurring operational cost that is much easier to forecast and justify to stakeholders and boards of directors.

Technological Agility and the Battle Against Obsolescence

One of the most significant risks in healthcare technology management is the speed of innovation. A state-of-the-art imaging system purchased today might be surpassed by a more precise, faster model in three years. In a CAPEX world, the hospital is stuck with the older machine until it is fully depreciated or until a new capital cycle begins. Equipment as a service mitigates this “obsolescence trap” by building technology refreshes into the service contract. Since the provider owns the fleet, they are incentivized to keep the equipment updated to ensure peak performance and customer satisfaction. This ensures that patients always have access to the highest standards of care without the hospital needing to initiate a new procurement battle every few years.

Streamlining Maintenance and Operational Uptime

Beyond the financial and procurement advantages, equipment as a service integrates maintenance, repairs, and software updates into a single comprehensive package. In the old model, a machine breakdown often triggered a sequence of bureaucratic hurdles: getting quotes, securing approvals, and then waiting for parts. When equipment is delivered as a service, the provider is typically bound by strict service level agreements (SLAs) that guarantee a certain percentage of uptime. This places the burden of reliability squarely on the shoulders of the manufacturer or service partner. They are motivated to perform proactive maintenance and use remote monitoring to prevent failures before they occur, as their revenue is often tied to the machine’s availability.

Data-Driven Insights and Utilization Tracking

The “as-a-service” model naturally lends itself to deeper data integration. Providers of equipment as a service often include sophisticated tracking and analytics tools that monitor how frequently a machine is used and for which types of procedures. This data provides healthcare administrators with invaluable insights into clinical workflows and asset utilization. If a particular piece of equipment is underutilized, the contract might allow for it to be swapped for a different asset or for the service level to be adjusted. This level of granular control was previously impossible under ownership models, where an idle machine simply sat as a “sunk cost” on the balance sheet.

Risk Mitigation and Lifecycle Management

The lifecycle of medical equipment involves more than just purchase and use it includes rigorous regulatory compliance, cybersecurity updates, and ethical disposal. Managing these aspects in-house requires a significant amount of specialized expertise and administrative overhead. By leveraging equipment as a service, hospitals effectively outsource these risks to specialists. The service provider ensures that the equipment remains compliant with the latest healthcare regulations and that all data security protocols are strictly followed. This is especially critical in an era where medical devices are increasingly interconnected and vulnerable to cyber threats. The provider’s expertise in device security becomes a protective layer for the hospital’s overall network.

Furthermore, HHM Global notes that the environmental impact of medical waste is a growing concern. Professional equipment as a service providers usually have established “circular economy” practices for the end-of-life stage of their products. They can refurbish, recycle, or ethically dispose of old units far more efficiently than an individual hospital could. This not only supports the healthcare facility’s sustainability goals but also ensures that no hazardous materials or sensitive patient data are left on decommissioned hardware.

The Future of Procurement in Modern Healthcare Systems

As healthcare systems continue to consolidate and seek greater efficiencies, the adoption of equipment as a service is likely to accelerate. We are moving toward a future where hospitals see themselves as providers of care rather than owners of hardware. This “asset-light” strategy allows for greater focus on patient outcomes and staff satisfaction. Clinicians benefit from always having the most modern tools at their disposal, while administrators benefit from a financial model that is resilient to market volatility and technological disruption. The shift from CAPEX to OPEX is not merely an accounting trick it is a strategic repositioning that prepares healthcare organizations for the complexities of the 21st century.

In conclusion, the rise of equipment as a service represents a milestone in the maturity of the healthcare industry. It acknowledges that the value of medical technology lies in its use, not its ownership. By embracing this model, healthcare facilities can ensure they remain at the forefront of clinical excellence, maintain robust financial health, and offer the best possible care to their communities. The transition requires a change in mindset, moving away from the pride of ownership toward the efficiency of partnership, but the rewards in terms of flexibility, reliability, and innovation are well worth the effort.

At the core of the launch is a redesigned pulse sequence, which delivers ablation significantly faster than earlier iterations while maintaining equivalent lesion outcomes. According to the company, the updated system operates with a lower temperature profile and achieves ablation speeds up to five times faster than the previous sequence. Built on the foundation of the Varipulse platform that received CE mark approval in 2024, the system enters an increasingly competitive European market that includes technologies such as Volt (Abbott), Farapulse (Boston Scientific), PulseSelect (Medtronic), Globe (Kardium), Centauri (CardioFocus) and PulseMagic (MicroPort EP). The Varipulse PFA catheter is positioned as a continuation of Johnson & Johnson’s iterative approach to innovation in electrophysiology.

“The introduction of Varipulse Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the Varipulse Platform,” said Michael Bodner, company group chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “This launch demonstrates our dedication to continuously evolving PFA technologies based on real-world learnings and our scientific expertise, supporting physicians to deliver high-quality care and improved patient outcomes.”

The system maintains compatibility with the Carto 3 mapping system, which provides 3D cardiac mapping capabilities used in electrophysiology procedures. This integration enables features such as tissue proximity indicators to support accurate lesion placement. Early clinical use has been carried out within the VARIPURE multicenter, prospective, post-market follow-up study, with further data generation planned as part of the broader commercial rollout. The company also intends to present the technology and related findings at the European Heart Rhythm Association annual meeting and the EHRA PFA summit. The Varipulse PFA catheter remains investigational in the U.S.

“In our early experience, Varipulse Pro has been exceptionally smooth and easy to use,” said Dr. Tom De Potter, head of electrophysiology and associate director of the Heart Center, OLV Hospital, Aalst, Belgium. “The speed is particularly striking and contributes to more efficient procedures without compromising precision. The integration with CARTO mapping and intracardiac echocardiography (ICE) facilitate accurate positioning and consistent lesion delivery, contributing to a very positive procedural experience.”

With the expanded funding, AI Airlock is expected to scale its operations and support the development of sustainable regulatory pathways for AI-driven medical technologies. Delivered through collaboration between MHRA, DHSC, the NHS AI Team, and Team AB, the programme aligns with broader government strategies, including the AI Opportunities Action Plan, the Regulatory Action Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

Commenting on the development, James Pound, Executive Director, Innovation and Compliance, said:
“Securing this multi-year funding boost marks a pivotal moment for AI Airlock and for the safe and responsible advancement of AI in healthcare.
The programme has already shown how collaborative, real-world testing can uncover regulatory challenges early and help innovators bring high-quality, safe technologies to patients faster.
This additional investment will allow us to scale up and ultimately strengthen our ability to ensure that AI-powered medical devices can reach patients safely, efficiently and with the confidence of robust regulatory oversight.”

The AI Airlock programme has evolved steadily since its pilot launch in 2024, followed by a second phase in 2025 that broadened its scope. Early findings highlighted new regulatory complexities associated with AI medical devices, particularly around risk management, accuracy, and the need to anchor model outputs in verified clinical data. It also underscored the importance of explainability in AI systems to strengthen clinician trust, alongside the necessity for continuous post-market monitoring to detect performance shifts or over-reliance.

Building on these insights, the second phase has examined specific regulatory challenges, including AI-powered diagnostic tools, pre-determined change control plans (PCCPs), and evolving use cases of AI systems. The programme has tested a wide spectrum of technologies such as large language models, voice-enabled tools, and advanced diagnostics targeting cancer and rare diseases. Outputs from this phase, including reports and case studies, are expected in Summer 2026 and will guide the design of phase three. Findings are also feeding into the National AI Commission’s work on shaping future regulatory frameworks. As AI Airlock expands, it continues to play a central role in strengthening collaboration between regulators and industry, supporting safe innovation while maintaining a robust and future-ready regulatory environment for medical devices.

At the operational level, the BD® Pyxis™ Pro Dispensing Solution is engineered to improve how medications are stored, accessed, and managed within hospital environments. Its modular, stackable design allows for increased storage capacity within the same physical footprint, accommodating both refrigerated and ambient medications. This approach supports healthcare systems in adapting to shifting patient needs while maintaining consistent medication availability. Enhanced security features such as RFID badge scanning, wireless barcode scanners, and illuminated bins aim to strengthen controlled substance management and simplify medication retrieval processes. In this context, the AI medication dispensing system is positioned as a tool to reduce inefficiencies and disruptions across clinical workflows.

The expansion also includes plans to extend the AI-enabled BD Incada™ Analytics platform already established in the United States to European hospitals and health systems next year. Built on Amazon Web Services’ (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform integrates advanced AI capabilities, including natural language search in analytics. The system is designed to scale alongside the data generated by nearly three million connected BD devices, offering clinicians enterprise-wide visibility into medication inventory through customizable dashboards. These capabilities support pattern identification, improved medication availability, reduced waste, and enhanced labor efficiency.

To address regional requirements, BD will utilize the AWS European Sovereign Cloud, enabling EU healthcare systems to meet digital sovereignty standards while maintaining performance, security, and scalability. “BD’s innovations in medication management are setting a new standard for unified, data-driven healthcare operations,” said Esteban Rossi, vice president and general manager for Medication Management Solutions, EMEA at BD. “Delivering the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Platform directly to European hospitals empowers our customers to strengthen medication availability, improve efficiency and enhance patient care.” The Pyxis™ Pro Dispensing Solution is expected to be deployed across Europe in the coming months, with support for 15 languages.